Boston Scientific accounts are for healthcare professionals only.
Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.
My Boston Scientific account
Access your online applications and manage your customer profile.
Quick Links
Call customer care
The EKOS-PE study followed 137 patients for 3 years after they received EKOS treatment for massive and submassive PE. EKOS therapy was associated with significantly reduced the RV/LV diameter ratio, improved long-term RV function, and is associated with a low all-cause mortality rate and favorable perceived QoL post-procedure.
61.5%
Felt their lungs were 'much better'
65.4%
Had no interference with normal activity
69.2%
Had no pain around the shoulder blade or chest
The EKOS-PE Study is one of the first to demonstrate long-term clinical outcomes after use of EKOS for PE.
Safety
Mean follow-up 26.5 ± 17.2 months
7.2% all-cause mortality
During patient hospital stay
0.7% in-hospital adverse event rate
0.7% major bleeding (not ICH)
0.7% ischemic stroke
At 30 days
5.1% all cause readmission rate
0.7% PE-related readmission
Efficacy
Mean follow-up 5.2 ± 7.8 months
RV/LV Ratio decrease:
26.7%
Residual RV dysfunction
| None | 79% |
| Mild | 8% |
| Moderate | 8% |
| Severe | 5% |
Quality of life
Mean follow-up 37 ± 12 months
Substantial symptom improvement:
Enhanced functional capacity:
References
1. Sayfo, S. Evaluation of Long-Term Key Outcomes and Safety in Pulmonary Embolism: The EKOS-PE Study. Presented at the Cardiovascular Research Technologies Annual Conference. March 2025
